Category: Health

Categories
Health

F.D.A. Attaches Warning of Uncommon Nerve Syndrome to Johnson & Johnson Covid Vaccine

F.D.A. Will Attach Warning of Rare Nerve Syndrome to Johnson & Johnson Vaccine

The database shows only one possible death of a recipient of the Johnson & Johnson shot from Guillain-Barre Syndrome. But the man, a 57-year-old Delaware man, had also suffered a heart attack and stroke in the past four years, which raised questions about his April death.

Although it only requires a single dose and is easier to store than Pfizer and Moderna vaccines, Johnson & Johnson vaccination played only a minor role in the US vaccination campaign. One of the reasons for this is that a plant in Baltimore that was supposed to supply most of the cans in the country was closed for three months for violating the law. The factory, operated by Emergent BioSolutions, a subcontractor, was forced to discard the equivalent of 75 million cans on suspicion of contamination, significantly delaying deliveries to the federal government.

At the same time, demand for the shot collapsed after the safety break in April. At that time, 15 women in the United States and Europe who received the Johnson & Johnson injection were diagnosed with the coagulation disorder; three died. The CDC has now confirmed 38 cases of the disorder.

Regulatory authorities and federal health officials warned that women under the age of 50 in particular should be aware of the “rare but increased” risk of clotting. In the nearly three months since the hiatus ended, only about five million people in the U.S. have taken Johnson & Johnson’s recording, and state officials report that people are much more cautious. Millions of cans distributed by the federal government sit unused and expire this summer.

Alex Gorsky, CEO of Johnson & Johnson, said last month he was still confident that the vaccine, which has been used in 27 countries, will help contain the pandemic overseas. The company has pledged up to 400 million cans to the African Union. Regardless, Covax, the global vaccine exchange program, is set to receive hundreds of millions of doses.

Studies have shown that the Johnson & Johnson syringe protects people from more contagious variants of the coronavirus, including the Delta variant, and is highly effective in preventing severe Covid-19, hospitalizations, and death.

The Food and Drug Administration shares responsibility for vaccines with the CDC, but is solely responsible for issuing product warnings. The Guillain-Barré cases will be discussed at an upcoming meeting of a committee of external experts advising the CDC, the agency said.

Categories
Health

Dr. Kavita Patel says want for a Covid booster shot appears inevitable

Dr. Kavita Patel says need for a Covid booster shot seems inevitable

Former Obama administration official Dr. Kavita Patel told CNBC on Monday that she expected a Covid vaccine booster to eventually be approved by U.S. regulators due to new, more transmissible variants of coronavirus.

“With the threat of the Delta variant and possibly other looming variants in the future, it seems inevitable that we will need a booster shot,” Patel said on Squawk Box. “But that trillion dollar question is when? It seems like six months is early.”

The comments from Patel, who now works as a family doctor in Washington, came before Pfizer representatives met with federal health officials on Monday to discuss the possible need for Covid booster vaccinations.

Pfizer recently said it is developing a booster shot to combat the highly transmissible Delta variant. In that announcement, the drug maker cited internal data and a study in Israel showing that six months after vaccination, people experience decreased immunity from Pfizer’s two-dose vaccine as Delta becomes the predominant variant in the country.

The company said a third dose of its existing vaccine could help boost immunity. Over the past few months, executives at Pfizer and its German partner BioNTech have said that people will likely need a third dose of vaccine within a year of being fully vaccinated.

However, shortly after Pfizer’s announcement last week, the Centers for Disease Control and Prevention and the Food and Drug Administration released a joint statement stating that fully vaccinated Americans do not currently need a booster vaccination.

This view is supported by health experts like Dr. Ashish Jha, dean of Brown University’s School of Public Health, shared. Jha told CNBC on Friday that he had “seen no evidence yet that anyone needs a third shot”.

While Patel said the data suggests that all three of the Covid vaccines currently approved in the US – the two-dose Pfizer and Moderna vaccines and the Johnson & Johnson single-dose vaccine – offer “more than enough immunity” To protect against severe hospitalization and death, Pfizer did not criticize Pfizer for working on the booster intake.

“I think what we do know is that, even six months ago, immunity declines over time. The question is, how long? ”Said Patel, who served as policy director for the Bureau of Interstate Affairs and Public Engagement in the Obama administration.

People shouldn’t get a third vaccination now, Patel warned.

“We have seen patients who did this accidentally or even deliberately, and they had even more dramatic side effects than the second shot, so I wouldn’t encourage anyone,” said Patel.

Finally, if a booster is recommended by regulators, people should expect the CDC to make recommendations for specific populations, similar to what happened when the vaccine was initially introduced with a focus on high-risk groups. “It won’t come one, it will all,” she said.

Patel said the conversation about booster shots in the US must take into account the global impact, given the difficult introduction in other parts of the world.

“It won’t help the United States if the rest of the world stays unvaccinated and they have the opportunity to get hundreds of millions of doses because we got a booster,” said Patel.

Categories
Health

U.S. Officers Push Again on Pfizer’s Request for Booster Shot Approval

U.S. Officials Push Back on Pfizer’s Request for Booster Shot Approval

Pfizer officials met privately with senior U.S. scientists and regulators on Monday to press for rapid approval of booster coronavirus vaccines amid growing public confusion over whether they are needed and opposition from federal health officials who say that the additional doses are now not required.

The high-level online meeting, which lasted an hour, and at which Pfizer’s chief scientist briefed virtually every top doctor in the federal government, took place the same day Israel began feeding heart transplant patients and others on the third dose of the Pfizer BioNTech vaccine administer weakened immune system. Officials said after the meeting that more data – and possibly several months – would be needed before regulators could determine whether booster injections were needed.

The two developments underscored the intensifying debate about whether booster injections are required in the US, when and for whom. Many American experts, including Dr. Anthony S. Fauci, President Biden’s senior medical advisor on the pandemic, have said there isn’t enough evidence yet that boosters are necessary. However, some say Israel’s move may anticipate a government decision to recommend it to at least the weak.

Pfizer is collecting information on antibody responses from those receiving a third dose, as well as data from Israel, and expects to share at least part of that in a formal application to the Food and Drug Administration for its coronavirus vaccine to expand its emergency clearance in the coming weeks.

However, the final decision on booster vaccination, several officials said after the meeting, will also depend on real-world information the Centers for Disease Control and Prevention has gathered about breakthrough infections – those that occur in people who have been vaccinated – who are serious or ill Cause hospital stays.

And any booster vaccination recommendations are likely to be calibrated within age groups as well, officials said. For example, if booster shots are recommended, they could first go to residents of nursing homes who received their vaccines in late 2020 or early 2021, while older people who received their first vaccinations in the spring may have to wait longer. And then the question arises, what kind of booster: a third dose of the original vaccine or perhaps a vaccination tailored to the highly contagious Delta variant, which is on the rise in the USA.

“It was an interesting meeting. They shared their data. There was nothing like a decision, ”said Dr. Fauci in a short interview Monday night, adding, “This is just part of a much bigger puzzle, and it’s part of the data, so there’s no question of a compelling case either way.”

Amy Rose, a Pfizer spokeswoman, said in a statement, “We had a productive meeting with US public health officials about elements of our research program and preliminary booster data.”

The Ministry of Health and Welfare, which convened the meeting, issued its own statement confirming the government’s stance. “At this point, fully vaccinated Americans don’t need a booster dose,” it said.

With less than half of the United States’ population being fully vaccinated, some experts said Monday the country must continue to focus on giving all Americans their first dose. The most important task of the Food and Drug Administration is to increase public confidence by granting full approval to the coronavirus vaccines used, which are initially approved in an emergency.

“At this point the most important strengthening we need is vaccinating people,” said Dr. Carlos del Rio, an infectious disease expert at Emory University in Atlanta. The booster doses in Israel, he added, “will help us answer some questions, but at the end of the day I disagree with what they are doing. I think it’s terribly premature. “

Within the Biden government, some fear that if Americans are convinced that coronavirus vaccines only offer short-lived immunity before needing a boost, they are less likely to accept vaccination. Those concerns could fall by the wayside, however, if new data from Israel, expected in the next few weeks, conclusively shows that immunity wears off after six to eight months, significantly increasing the risks for the elderly or other vulnerable populations.

The government convened the meeting on Monday in response to the announcement last week by Pfizer and its German partner BioNTech that they would develop a version of their vaccine targeting the Delta variant and reported promising results from studies with people who A third dose of the vaccine received original vaccine six months after the second.

The new dates Not yet published or peer-reviewed, but as announced by companies that they would submit data to the Food and Drug Administration to approve booster vaccinations surprised the Biden White House.

In an unusual joint statement Thursday evening, hours after Pfizer-BioNTech’s announcement, the FDA and CDC pushed back.

“Americans who are fully vaccinated currently do not need a booster,” the statement said, adding, “We are prepared for booster doses when and when science shows they are needed.”

The move can make economic sense for Pfizer-BioNTech. Since the outbreak of the pandemic, the partner companies have been following a “get to market first” strategy in the manufacture and marketing of their vaccines.

The companies did not accept federal funds or participate in Operation Warp Speed, former President Donald J. Trump’s fast-track vaccine initiative. Not only were they the first to get Food and Drug Administration approval for their coronavirus vaccine, the first to use the novel mRNA technology, but also the first to get their vaccine approved in adolescents.

The strategy has “paid off as well as you could wish,” said Steve Brozak, president of WBB Securities, a biotechnology-focused research investment bank.

Last week, Pfizer and BioNTech said a booster given six months after the second dose of the vaccine increased the effectiveness of antibodies against the original virus and beta variant by five to ten times. But antibody levels may not be the best biological measure of need for booster doses, say experts, who say it’s no surprise that antibodies increase after a third dose.

“The antibody response is not the only measure of immune protection,” said Dr. Leana S. Wen, a former health commissioner for Baltimore. “There have been several studies to suggest that these vaccines also stimulate B-cell and T-cell immunity. Even if there aren’t that many antibodies, it doesn’t mean someone isn’t protected. “

In Israel, the government has agreed to provide Pfizer with data on its vaccine recipients, and Pfizer has cross-checked the Israeli data with the results of its own laboratory tests. Some people familiar with the data say this suggests that those vaccinated may lose immunity after about six to eight months, leading to an increasing number of breakthrough infections.

The participants in Monday’s meeting were a who’s who of government doctors: Dr. Fauci; Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention; Dr. Francis Collins, the director of the National Institutes of Health; Dr. Vivek Murthy, the general surgeon; Dr. Rachel Levine, the assistant secretary of health; Dr. Janet Woodcock, acting FDA commissioner; Dr. Peter Marks, the director of the FDA’s Center for Biologics Evaluation and Research; and Dr. David Kessler, a former FDA commissioner who, among other things, leads the Biden government’s vaccine distribution efforts.

Dr. Del Rio, of Emory University, complained that the meeting was held privately on Monday instead of Pfizer publicly presenting its dates to the CDC’s Advisory Committee on Vaccine Practices, which will ultimately recommend whether booster injections are needed.

Just over two-thirds of American adults – 67.7 percent – got at least one Covid-19 shot, according to the CDC. The president had hoped to have at least partially vaccinated 70 percent of adults by July 4th.

Still, the national vaccination campaign has made it clear that the vaccine is successful in preventing disease, and studies suggest that vaccines against the Delta variant remain effective. Outbreaks occur in areas with low vaccination rates and the number of national cases has increased recently; according to a database from the New York Times.

World Health Organization officials on Monday stressed the importance of prioritizing global vaccine production and distribution over booster development, given the large gaps between countries’ vaccine programs.

“That doesn’t mean one or the other; it brings order to a crisis, ”said Dr. Michael Ryan, the organisation’s executive director of the emergency health program, on what the organization calls a two-stage pandemic.

Lauren McCarthy contributed to the coverage.

Categories
Health

Most absolutely vaccinated individuals who get Covid delta infections are asymptomatic, WHO says

Most fully vaccinated people who get Covid delta infections are asymptomatic, WHO says

World Health Organization Director General Tedros Adhanom Ghebreyesus R speaks at a daily briefing in Geneva, Switzerland.

Chen Junxia | Xinhua News Agency | Getty Images

People fully vaccinated against Covid-19 still get the Delta variant, but global health officials said the vaccinations saved most people from getting seriously ill or dying.

“There are reports that vaccinated populations have cases of infection, particularly with the Delta variant,” said Dr. Soumya Swaminathan, the chief scientist of the World Health Organization, at a press conference on Monday. “Most of these are mild or asymptomatic infections.”

However, hospital admissions are on the rise in some parts of the world, especially where vaccination rates are low and the highly contagious Delta variant is spreading, she said.

In the US, officials said virtually all recent hospital admissions and deaths from Covid have occurred in people who have not been vaccinated. Breakthrough infections are rare, and about 75% of people who die or are hospitalized after being vaccinated with Covid are over 65, according to the Centers for Disease Control and Prevention.

“The Delta variant is spreading around the world at a breakneck pace, driving the number of cases and deaths again. However, the same hit does not suffer everywhere,” said WHO Director General Tedros Adhanom Ghebreyesus. “We are in the midst of a growing two-pronged pandemic, with the haves and the have-nots growing divergent within and between countries in high-vaccination locations.”

The variant spreads quickly and infects unprotected and vulnerable people, he said.

Swaminathan warned that vaccinated people can still get Covid and pass it on to others, which is why WHO officials have urged people to continue wearing masks and practice social distancing. “But it certainly greatly reduces your chances of severe hospitalization and death,” she added.

Some studies have shown that those who are infected with Covid after vaccination produce much fewer virus than those who are not vaccinated, which reduces the risk of spreading the virus to others. WHO officials said more studies are needed to understand the impact of the vaccines on transmissibility.

Categories
Health

F.D.A. Will Connect Warning of Uncommon Nerve Syndrome to Johnson & Johnson Vaccine

F.D.A. Will Attach Warning of Rare Nerve Syndrome to Johnson & Johnson Vaccine

The Food and Drug Administration is planning to warn that Johnson & Johnson’s coronavirus vaccine can lead to an increased risk of a rare neurological condition known as Guillain–Barré syndrome, another setback for a vaccine that has largely been sidelined in the United States because of manufacturing problems and a temporary safety pause earlier this year, according to several people familiar with the plans.

Although regulators have found that the chances of developing the condition are low, they appear to be three to five times higher among recipients of the Johnson & Johnson vaccine than among the general population in the United States, according to people familiar with the decision.

Federal officials have identified roughly 100 suspected cases of Guillain-Barré disease among recipients of the Johnson & Johnson shot through a federal monitoring system that relies on patients and health care providers to report adverse effects of vaccines. The reports are considered preliminary. Most people who develop the condition recover.

The F.D.A. has concluded that the benefits of the vaccine in preventing severe disease or death from the coronavirus still very much outweigh any danger, but it plans to include the proviso in fact sheets about the drug for providers and patients

“It’s not surprising to find these types of adverse events associated with vaccination,” said Dr. Luciana Borio, a former acting chief scientist at the F.D.A. under President Barack Obama. The data collected so far by the F.D.A., she added, suggested that the vaccine’s benefits “continue to vastly outweigh the risks.”

In a statement released Monday, the Centers for Disease Control and Prevention said the cases have largely been reported about two weeks after vaccination and mostly in males, many aged 50 years and older.

The database reports indicate that symptoms of Guillain-Barré developed within about three weeks of vaccination. One recipient, a 57-year-old man from Delaware who had suffered both a heart attack and a stroke within the last four years, died in early April after he was vaccinated and developed Guillain-Barré syndrome, according to a report filed to the database.

The Biden administration is expected to announce the new warning as early as Tuesday. European regulators may soon follow suit. No link has been found between Guillain-Barré syndrome and the coronavirus vaccines developed by Pfizer-BioNTech or Moderna, the other two federally authorized manufacturers. Those rely on a different technology.

Nearly 13 million people in the United States have received Johnson & Johnson’s shot, but 92 percent of Americans who have been fully vaccinated received shots developed by Pfizer-BioNTech or Moderna. Even though it requires only one dose, Johnson & Johnson’s vaccine has been marginalized by manufacturing delays and a 10-day pause while investigators studied whether it was linked to a rare but serious blood clotting disorder in women. That investigation also resulted in a warning added to the fact sheet.

The new safety concern comes at a precipitous moment in the nation’s fight against Covid-19. The pace of vaccinations has slowed considerably just as a new, more contagious variant called Delta is spreading fast in under-vaccinated areas. Federal health officials are worried that the news could make some people even more hesitant to accept the vaccines developed by Pfizer-BioNTech or Moderna, even though well over 100 million people have received those vaccines, according to the Centers for Disease Control and Prevention.

Updated 

July 12, 2021, 2:12 p.m. ET

Almost one-third of the nation’s adults remain unvaccinated. The Biden administration has shifted away from relying on mass vaccination sites and is now enlisting community workers in door-to-door campaigns, supplying doses to primary care doctors and expanding mobile clinics in an attempt to convince the unvaccinated to accept shots.

Johnson & Johnson’s vaccine has played a minor role in the nation’s inoculation campaign partly because the Baltimore plant that was supposed to supply most of the doses to the United States has been shut down for three months because of regulatory violations. The factory, operated by Emergent BioSolutions, a subcontractor, has been forced to throw out the equivalent of 75 million doses because of suspected contamination, severely delaying deliveries to the federal government.

Demand for the shot also plummeted after the April safety pause. At that time, 15 women in United States and Europe who had received the Johnson & Johnson shot had been diagnosed with the disorder. Three had died.

Regulators ultimately decided that the risk was remote and far outweighed by the benefits. They attached a warning to the drug and cleared it for use, but state officials have said that the perception that the vaccine might be unsafe hurt it.

Alex Gorsky, Johnson & Johnson’s chief executive, said last month that he was still hopeful that the vaccine, which has been used in 27 countries so far, would help contain the pandemic overseas. The company has promised up to 400 million doses to the African Union. Separately, Covax, the global vaccine-sharing program, is supposed to receive hundreds of millions of doses.

Studies have showed that the Johnson & Johnson shot protects people against more contagious virus variants, including the Delta variant, and is highly effective at preventing severe Covid-19, hospitalizations and death.

The F.D.A. shares jurisdiction over vaccines with the Centers for Disease Control and Prevention but is responsible for issuing product warnings. The Guillain-Barré cases are expected to be discussed in an upcoming meeting of a committee of outside experts who advise the C.D.C.

The F.D.A. has also attached a warning to the Pfizer-BioNTech and Moderna vaccines, but some health officials described that as less serious than the warnings about Johnson & Johnson. Last month, the agency warned about an increased risk of inflammation of the heart or the tissue surrounding it — diseases known as myocarditis and pericarditis — particularly among adolescents and young adults who had received Pfizer-BioNTech or Moderna shots. But the C.D.C. said in most cases, symptoms promptly improved after simple rest or medication.

The Guillian-Barré syndrome is more likely to result in medical intervention, officials said. It occurs when the immune system damages nerve cells, causing muscle weakness and occasional paralysis, according to the F.D.A. Several thousand people — or roughly 10 out of every one million residents — develop the condition every year in the United States. Most fully recover from even the most severe symptoms, but in rare cases patients can suffer near-total paralysis.

The suspected cases were reported in the Vaccine Adverse Event Reporting System, or VAERS, a 30-year-old federal monitoring system. So far, researchers have not identified any particular demographic pattern, but the many of the reports in the publicly available database indicate that the patients were hospitalized.

Guillain-Barré syndrome has also been linked to other vaccines. The Centers for Disease Control and Prevention has said that flu vaccines, including the 1976 swine flu vaccine, led to a small increased risk of contracting the syndrome, although some studies suggested that people are more likely to develop Guillain-Barré from the flu itself than from flu vaccines. Earlier this year, the F.D.A. warned that GlaxoSmithKline’s shingles vaccine, Shingrix, could also increase the risk of the disease.

Only about five million people in the U.S. have taken Johnson & Johnson’s shot since the April pause was lifted. Millions of doses that have been distributed by the federal government are sitting unused and will expire this summer.

Apoorva Mandavilli and Carl Zimmer contributed reporting.

Categories
Health

Pfizer to make case to U.S. officers Monday

Pfizer to make case to U.S. officials Monday

Long Beach City Department of Health & Human Services is hosting an evening COVID-19 Vaccination Clinic on Long Beach City College Pacific Coast Campus. on Tuesday, July 6, 2021 in Long Beach, CA.

Francine Orr | Los Angeles Times | Getty Images

Pfizer meets with federal health officials on Monday to discuss the need for Covid-19 vaccine booster vaccinations as the drug company prepares for U.S. approval for a third vaccination, the company confirmed.

The meeting comes amid a public dispute between the drug maker and U.S. officials as to whether and when Americans will need additional doses of the Covid vaccines. Pfizer announced on Thursday that its two-dose vaccine, developed with German partner BioNTech, has seen a decrease in immunity and is now planning to apply for approval for a booster dose.

But shortly after Pfizer’s announcement, the Centers for Disease Control and Prevention and the Food and Drug Administration issued a joint statement condemning the company’s comments saying that Americans who were fully vaccinated against Covid are currently do not need a booster vaccination.

The debate about booster vaccination comes as the public becomes increasingly concerned about the highly communicable Delta variant – which is already the predominant form of the disease in the US – and whether current regimens of approved vaccines provide adequate protection.

Invitees include White House Chief Medical Officer Dr. Anthony Fauci, Dr. Francis Collins, Director of the National Institutes of Health, CDC Director Dr. Rochelle Walensky and Acting FDA Commissioner Dr. Janet Woodcock.

The White House and the Department of Health declined to comment.

“It’s very unusual and frustrating,” said Dr. Paul Offit, who advises the FDA on Covid vaccines, about the meeting on Monday. “Pfizer is a pharmaceutical company. You are not a public health agency. It is not up to them to determine how this vaccine will be distributed in terms of booster doses. That depends on the epidemiological work of the CDC. “

Offit said there is currently no data to suggest that most Americans still need booster doses. If officials see an increase in the percentage of fully vaccinated people who go to hospital or die, it could be time for the booster, he said.

“Right now that percentage is less than 1%,” he said. “Maybe over a year it’s 5% and a year later it’s 10-20%” of hospital admissions and deaths are fully vaccinated people.

Pfizer has cited data from Israel showing that its vaccine continues to be highly effective in serious illness and death, but wears off in mild cases.

Last week, Israeli officials reported a decrease in the effectiveness of the Pfizer BioNTech vaccine in preventing infections and symptomatic diseases, but said it remained highly effective in preventing serious diseases.

Dr. Isaac Bogoch, professor of infectious diseases at the University of Toronto, called Israel’s report on vaccine effectiveness “flawed” because it was an observational study from a single source.

People want to say, “Delta is going into vaccines,” he said. “That is not the case. This is quickly becoming the disease of the unvaccinated. We have to learn to differentiate between infection and disease.”

He said the vaccines in the US offer “excellent protection against” variants, including Delta.

“There may be a need for boosters in select populations, such as the immunocompromised, and we should be receptive to the need for boosters in the general population. But there doesn’t seem to be a need right now, ”he said hey.

Categories
Health

BioBonds Use Wall Road Instruments to Fund Medical Analysis

BioBonds Use Wall Street Tools to Fund Medical Research

In disease treatment development, the phase between basic research and advanced clinical trials is referred to as the “valley of death”.

While early-stage research is abundantly funded with public grants and pharmaceutical companies are willing to fund trials of proven solutions, research in the “translational” stage, where basic knowledge is applied to potential treatments, is notoriously difficult to fund. As a result, some promising treatments are never pursued.

The pandemic has made this dangerous valley “much deeper,” said Karen Petrou, co-founder and managing partner of Federal Financial Analytics, a Washington financial services advisory firm that has developed a new financial tool designed to help solve this problem.

During the pandemic, clinical trials were halted, resources withdrawn from laboratories, attention turned to immediate needs, and many resources dried up. New research projects were difficult to start.

At the same time, the value of funding scientific research became even clearer: without the initial efforts of academic laboratories, it would have been impossible for large pharmaceutical companies to accelerate vaccine development.

The solution proposed by Ms. Petrou, known as BioBonds, gained in importance.

The program would create low-interest, government-sponsored loans for translational research. Similar to mortgages, these would be wrapped in a bond and sold on the secondary market to risk-averse institutional investors such as pension funds.

In May, Rep. Bobby Rush, Democrat from Illinois, and Rep. Brian Fitzpatrick, Republican from Pennsylvania introduced a bill that, if passed, would create these $ 30 billion worth of three-year loans.

Ms. Petrou, who was diagnosed with retinal degeneration as a teenager and went blind in her 40s, first stumbled upon the “Valley of Death” in 2013. She raised money for studies to expedite retinal degeneration treatment, but potential investors said your translational projects were too speculative – they needed results that show a potential idea works, preferably with a large population dependent on pills.

She refused to take this as a definitive answer. Many countries support private sector funding for biomedical research, and each does it differently, Ms. Petrou said, “We needed an American model.”

Ms. Petrou and her husband Basil have advised Wall Street executives and regulators for decades. (She recently wrote a book on monetary policy that promotes inequality.) You had thought a lot about mixed public-private markets during the mortgage finance crisis. Inspired by green bonds – publicly secured loans that have created a $ 750 billion private market for sustainability projects since 2007 – they started work on the idea that became BioBonds.

“It’s a lifeline,” said Attila Seyhan, director of translational oncology at Brown University and a former Pfizer scientist, of the idea. He said his colleagues were equally intrigued.

Unlike grants, the researchers would have to repay BioBonds loans. Still, it is a “constant struggle,” said Dr. Seyhan, getting full funding, and “there is tremendous frustration with the lack of alternatives.”

He believes that university divisions are getting “creative” to make BioBonds work. “There will be losses,” he said. “But if 1 percent is successful, you pay off the losses. This is how drug development works. “

Daily business briefing

Updated

July 9, 2021, 6:58 p.m. ET

Many schools are already encouraging scholars to find funding outside of grants to pursue their ideas. Scientists are increasingly saying that they need to think like venture capitalists and keep commercialization in mind when designing clinical trials so they can raise money from private companies to fund them.

“Even if we discover something, universities have to help researchers make the transition to commercialization,” says Dr. Richard Burkhart, surgeon and researcher at Johns Hopkins University School of Medicine. His work is currently funded by the National Institutes of Health, but he is working with his institution’s Technology Ventures team to commercialize his work.

While grants are preferable, they are not abundant. Dr. Burkhart believes BioBonds can help scientists and institutions navigate difficult translational space.

When Petrous first developed the BioBond concept, they proposed a modest pilot program to study blindness. The law was introduced in the 2018 session in the House of Representatives and in a new session in 2019. Then everything changed. “Covid hit and US biomedicine just stopped,” Ms. Petrou recalled.

Meanwhile, the couple’s understanding of the need for more translational research tragically developed. Mr. Petrou was diagnosed with pancreatic cancer in 2018. After an operation in 2019 as part of a clinical study by Dr. Burkhart, Mr. Petrou was considered cancer-free. But in April last year, a routine check-up showed the disease had come back.

The Petrous were determined to find another trial, but thousands of them were stopped because of the pandemic. They were stuck in lockdown at home and decided to rethink their BioBonds idea but think bigger. They repurposed and expanded their initial proposal to relieve the added stress on the already ailing translational space.

“When we started hearing about the havoc in the context of clinical trials, I was quick to turn around,” said Valerie White, a recently retired financial services lobbyist, formerly with Akin Gump. She had helped develop the original bond concept and immediately began talking to contacts in Congress about BioBonds.

Legislation introduced by Mr. Rush and Mr. Fitzpatrick in May called the Long-term Opportunities for Advancing New Studies for Biomedical Research Act, or LOANS for Biomedical Research, would require the Secretary of Health to guarantee US $ 10 billion a year for three years to fund loans to universities and other laboratories to conduct FDA-approved clinical trials. The bill is supported by 14 co-sponsors and about 20 organizations, including the Alliance for Aging Research, Alzheimer’s Drug Discovery Association, Blinded Veterans Association, and the Juvenile Diabetes Research Foundation.

“This should, quite frankly, attract the attention of many different sectors in Congress,” said Ms. White. In their view, more biomedical research will not only save lives, but also lead to increased military readiness and profitability, among other things.

She volunteered for the project for four years and said she would continue until the BioBonds Act goes into effect.

Mr Petrou will not be there to celebrate when that day comes. He died in March. Ms. Petrou believes the surgery he underwent as part of the clinical trial would have saved his life had it not been for other complications.

Ms. Petrou is determined to see the LOANS Act passed to pay tribute to her partner for more than a quarter of a century. She thinks a lot about all the pain people are going through now, fear that could be avoided in the future if more work was done on all kinds of remedies, including cancer and blindness.

“That was their baby from the start,” said Ms. White, who was present at the couple’s wedding and remained friends with them over the years. “It’s almost ironic that this whole project started with eye contacts that could have helped Karen, but in the end Basil could have benefited if that idea had existed before.”

Categories
Health

England anticipated to substantiate lockdown lifting regardless of fears over delta surge

England expected to confirm lockdown lifting despite fears over delta surge

Football fans wrapped in English flags stand in front of Wembley Stadium ahead of the Euro 2020 England v Italy final.

SOPA pictures | LightRakete | Getty Images

LONDON – UK Prime Minister Boris Johnson is expected to confirm on Monday that the final easing of lockdown rules in England will take place on July 19th.

The move comes despite a sustained surge in coronavirus cases caused by the more contagious Delta variant. Over 31,000 new cases were reported in the UK on Sunday.

However, Johnson is expected to caution as the country reopens, stressing that some public actions, such as the wearing of masks, are a matter of personal responsibility and sensible choice. Johnson had previously said Covid should “become a virus we learn to live with,” like the flu.

In comments the government released Monday morning, Johnson said, “We’re temptingly close to the final milestone on our lockdown roadmap, but the plan to restore our freedoms must come with a warning.”

“While the phenomenal introduction of vaccines has offered every adult some protection from the virus and the critical link between cases, hospital admissions and deaths has been weakened, the global pandemic is not over.”

Johnson said Covid cases will increase if the country is unlocked. “As we confirm our plans today, our message will be clear. Caution is absolutely essential. “

Freedom Day – or step 4 in the government’s long-term plan to ease restrictions – has been postponed to July 19, after it was previously scheduled for June 21.

The government has said that “four tests” to relax Covid restrictions must be passed before relaxation can continue, including examining data to confirm vaccine adoption continues successfully and infection rates do not spike in hospital stays take risk.

The latest data will be presented on Monday, “with current modeling suggesting that Covid cases will continue to increase if restrictions are relaxed,” the government said in a statement on Monday.

“Hospitalizations, serious illnesses and deaths will also continue, albeit at a much lower level than before the vaccination program,” it said.

The delay in easing restrictions came when the variant of Delta Covid, originally discovered in India, spread across the country. While infection rates have increased, hospital admissions and deaths have not increased (although there was a slight increase in these latter two records), suggesting that coronavirus vaccines are preventing serious infections.

The analysis suggests that the Pfizer BioNTech vaccine is 96% effective against hospitalization after two doses and the Oxford-AstraZeneca vaccine is 92% effective.

The UK’s Covid vaccination program has been one of the fastest in the world, with 87.1% of the adult population now receiving a first dose of a vaccine and 66% two doses, government data shows.

The government said Monday that vaccination rollout will be further accelerated by moving second doses for under 40 to eight weeks.

Categories
Health

The Rationing of a Final-Resort Covid Remedy

The Rationing of a Last-Resort Covid Treatment

The results vary widely between hospitals. Overall, however, survival rates have decreased over time, including in large US and European hospitals. From January to May 2020, according to the international register, less than 40 percent of Covid patients died in the first 90 days after the start of ECMO. But more than half died in the months that followed. “The patients seem to be doing significantly worse,” said Dr. Barbaro.

He and his colleagues analyze whether this is related to factors such as new virus variants, less experienced care centers or changes in the treatment of patients before ECMO.

ECMO is offered in a few community hospitals that care for most Americans. The exception is Saint John’s, the Santa Monica facility where the doctor and police sergeant were treated.

An ECMO program started about a year before the advent of Covid-19. The 266-bed hospital provided therapy to 52 Covid patients during the pandemic, much like the entire Northwell healthcare system in New York, which has more than 6,000 hospital and long-term care beds.

The Saint John’s Charity Foundation, supported by the area’s affluent donor base, helped fund the ECMO program and its expansion. The hospital accepted some uninsured Covid patients for ECMO, while those patients elsewhere were often turned down despite a federal program that reimburses hospitals for their treatment.

“There are just so many inequalities,” said Dr. Hammond, director of the Saint John intensive care unit. And for every Covid patient who has survived with ECMO, there are “probably three, four, five people who will die on the waiting list”.

She and other doctors said the pandemic highlighted the need to make ECMO more widely available and less resource intensive. Until then, “we really need a sharing system,” she said. There are allocation systems for transplant organs and trauma care.

Categories
Health

5 issues to know earlier than the inventory market opens Thursday, July 8

5 things to know before the stock market opens Thursday, July 8

Here are the most important news, trends and analysis that investors need to start their trading day:

1. Dow to drop 500 points as Covid concerns resurface

Traders work on the floor of the New York Stock Exchange.

Brendan McDermid | Reuters

Dow futures on Thursday fell nearly 500 points, or more than 1.3%, in a broad premarket decline as Japan declared a state of emergency in Tokyo for the upcoming Summer Olympics and as countries deal with a rebound in Covid cases due to variants. Futures tied to the S&P 500 and Nasdaq also dropped about 1.3% each.

Thursday’s selling came one day after Wall Street’s rally had resumed, with the S&P 500 and Nasdaq finishing at record high closes. The Dow Jones Industrial Average ended 0.3% shy of Friday’s record close.

2. 10-year Treasury yield falls on global economic growth worries

Investors rotated into the perceived safety of bonds Thursday, pushing the 10-year Treasury yield below 1.26% to the lowest since late February. Bond yields move inversely to prices.

  • Despite the strengthening economy and hotter inflation, the 10-year yield continues to decline.
  • It began July around 1.58%. It hit a then-14-month high of 1.78% in March.
  • It began 2021 at less than 1%.

In another look at the recovery in the labor market, the government Thursday morning said initial jobless claims for last week totaled a worse-than-expected 373,000. That’s up slightly from the upwardly revised pandemic-era low the previous week. The level of continuing claims decreased to 3.34 million, down 145,000 from the previous week’s revised level.

3. Tokyo to go under state of emergency ahead of Olympics

The logo of Tokyo 2020 is displayed near Odaiba Seaside Park in Tokyo on July 7, 2021, as reports said the Japanese government plans to impose a virus state of emergency in Tokyo during the Olympics.

Kazuhiro Nogi | AFP | Getty Images

Just two weeks before the Tokyo Olympics, Japan’s prime minister on Thursday announced the state of emergency for the capital city due to rising Covid infections. The order goes into effect this coming Monday and through Aug. 22. That means the Olympics, opening on July 23 and running through Aug. 8, will be held entirely under emergency measures. While fans from abroad were banned months ago, Olympics officials had recently set venue limits at 50% capacity for local spectators. However, the state of emergency could force another change in the fan policy.

4. Global coronavirus deaths top 4 million as delta variant spreads

Two women walk next to graves of people who passed away due to the coronavirus disease (COVID-19) at the Parque Taruma cemetery in Manaus, Brazil May 20, 2021.

Bruno Kelly | Reuters

The global death toll from Covid exceeded 4 million late Wednesday as infections worldwide crossed 185 million, according to data compiled by Johns Hopkins University. In recent months, many countries are battling a surge in Covid infections due to the spread of the more transmissible delta variant, which first emerged in India. The delta strain now accounts for more than half of new Covid cases in the U.S. The World Health Organization has said that delta is the “fastest and fittest” variant yet, and health experts have warned it could undermine efforts to contain Covid even as vaccination campaigns are underway around the globe.

5. States bring new antitrust suit against Google over app store

The logo of Google Play is seen on a screen.

Alexander Pohl | NurPhoto | Getty Images

State attorneys general are again going after Google with an antitrust lawsuit, this time alleging the Alphabet unit abused its power over app developers through its Play Store on Android. The case marks the fourth antitrust lawsuit lodged against the company by U.S. government enforcers in the past year. By focusing on the Play Store, the latest lawsuit touches on an aspect of Google’s business that is most similar to Apple’s App Store. The App Store has become embattled in legal challenges and drawn lawmaker questions over whether it unfairly charges developers for payments through their apps by customers and whether it favors its own apps over those of its rivals.

— The Associated Press contributed to this report. Follow all the market action like a pro on CNBC Pro. Get the latest on the pandemic with CNBC’s coronavirus coverage.

Disclosure: CNBC parent NBCUniversal owns NBC Sports and NBC Olympics. NBC Olympics is the U.S. broadcast rights holder to all Summer and Winter Games through 2032.